ライフサイエンスコーパス: PGG

1 PGG binds specifically to arterial elastin and, in doing

2 PGG glucan-treated animals showed increases in total leu

3 PGG is a gallotannin produced by a variety of medicinal

4 nic acid is converted to prostaglandin G(2) (PGG(2)) by the cyclooxygenase activities of prostaglandi

5 e arachidonic acid (AA), prostaglandin G(2) (PGG(2)), and cyclooxygenase 2 (COX-2).

6 the PGHS-cyclooxygenase, prostaglandin G(2) (PGG(2)), by elevating the concentration of either enzyme

7 We report here the purification of a PGG-glucan-binding element from human leukocytes and its

8 taglandin precursors, arachidonic acid (AA), PGG(2) and PGH(2).

9 o using cytotoxicity, elastin stability, and PGG-elastin interaction assays.

10 fferences from WT behavior occur in both apo PGG/GGG and in the form bound to the reaction-intermedia

11 g this time (and were often hotly debated at PGG meetings).

12 gest that the protective effect exhibited by PGG glucan in the rat peritonitis model is mediated, at

13 st neighbours on a cyclic network after each PGG round.

14 the fluid space was reduced to 5 A at an EPC:PGG mole ratio of 5:1.

15 espectively); similarly, the K(m) values for PGG(2) and 15-HETE formation by V349L oPGHS-1 were diffe

16 With native enzyme, the K(m) values for PGG(2), 11-HETE, and 15-HETE formation were each differe

17 3-proS hydrogen from arachidonate which, for PGG(2) formation, is followed by insertion of O(2) at C-

18 whether protection could be transferred from PGG glucan-treated animals to naive recipients via splee

19 peration in a large-scale public goods game (PGG).

20 -beta-glucotriosyl-(1-3)-beta-glucopyranose (PGG) glucan, a biological-response modifier, in protecti

21 -beta-glucotriosyl-(1-3)-beta-glucopyranose (PGG)-glucan and Bacteroides fragilis polysaccharide A (P

22 -anomers of penta-O-galloyl-D-glucopyranose (PGG), 2 and 3, act as insulin mimetics that bind to and

23 enols, only penta-O-galloyl-alpha-D-glucose (PGG) was able to completely mimic the effects of TA by c

24 tringency expressed in pentagalloyl glucose (PGG) units in concentrations ranging from 1 to 140mumol/

25 of aortic elastin with pentagalloyl glucose (PGG), an elastin-binding polyphenol, would interfere wit

26 e since the first Population Genetics Group (PGG) meeting in January 1968.

27 this in terms of altered loop-6 dynamics in PGG/GGG.

28 ical aspects were monitored and evaluated in PGG-treated aortas compared with saline-treated control

29 In response, low PGG contributors increase their contributions if both ne

30 With this model, PGG was delivered periadventitially at 2 separate time p

31 f wild-type (WT) TIM and a quintuple mutant (PGG/GGG).

32 The single-hinge mutants PGG and GGG had k(cat) values 200-fold lower than that o

33 , participants do not know their neighbours' PGG contribution and thus cannot link play in the PD to

34 portion of the in vivo antitumor activity of PGG may be the result of antiangiogenic activity mediate

35 on of acetaminophen, as does the addition of PGG(2) itself.

36 Periadventitial administration of PGG hinders the development of AAA in a clinically relev

37 y, oral or intraperitoneal administration of PGG inhibits angiogenesis in the mouse corneal micropock

38 a linear correlation of the concentration of PGG(2) with an LOD of 0.227microM.

39 The protective effect of PGG glucan was abrogated by treatment with indomethacin,

40 Safety and efficacy of PGG treatment were first tested in vitro using cytotoxic

41 For in vivo studies, the efficacy of PGG was evaluated within a well-established AAA model in

42 a reduction of the 15-hydroperoxyl group of PGG(2) to form PGH(2) catalyzed by the peroxidase activi

43 ventitial delivery of noncytotoxic levels of PGG inhibits elastin degeneration, attenuates aneurysmal

44 ified prostaglandin extract from the sera of PGG glucan-treated animals protected against mortality i

45 calability of this effect: in a 1,000-person PGG, participants in the treatment condition successfull

46 ble activity (t-Boc-PGP-OMe, N-acetyl-P, PG, PGG, GP, GG and gly-pro-hyp).

47 V349L oPGHS-1 formed primarily PGG(2), 15S-HETE, and 15R-HETE but only trace amounts of

48 Native forms of oPGHS-1 produced primarily PGG(2) but also several monohydroxy acids, which, in ord

49 The immunomodulator Betafectin(R) PGG-glucan is a homopolymer of glucose derived from yeas

50 Radiolabeled PGG-glucan bound several other neutral glycosphingolipid

51 The binding of radiolabeled PGG-glucan to lactosylceramide was not inhibited by glyc

52 The binding of radiolabeled PGG-glucan to purified lactosylceramide was saturable, s

53 ere found to support binding to radiolabeled PGG-glucan.

54 Previous work demonstrated that PGG/GGG has a tenfold higher Km value and 10(3)-fold red

55 now report the serendipitous discovery that PGG (1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranose) is

56 We find that PGG inhibits CMG2 with a submicromolar IC50 and it also

57 These data show that PGG/GGG exists in multiple conformations that are not fu

58 bserve a sharp decline of cooperation in the PGG, while in the treatment condition global cooperation

59 with neighbours who contribute little in the PGG.

60 -iso-prostaglandin F2alpha, an isomer of the PGG/H synthase (cyclooxygenase or COX) enzyme product, p

61 n and thus cannot link play in the PD to the PGG.

62 s to a much more international one (with the PGG meetings having made important contributions to the

63 he cyclooxygenase site of oPGHS-1 leading to PGG(2), 11R-HETE, and 15S-HETE and/or 15R-HETE, respecti

64 H(2), but does have a marked activity toward PGG(2) converting it to PGE(2) and 15-keto-PGE(2).

65 minal hinge was mutated to P166/V167G/W168G (PGG), and the C-terminal hinge was mutated to K174G/T175

66 eukocytes or serum from animals treated with PGG glucan.

67 initial oxygenation of arachidonate to yield PGG(2) catalyzed by the cyclooxygenase activity of the e

68 the molecule is optimally arranged to yield PGG(2) versus monohydroperoxy acid products (Val-349, Tr